surmount tirzepatide surmount-1 non-diabetic obesity trial For the first time, and semaglutide were put in SURPASS to SURMOUNT: The Tirzepatide

As for the comparison of oral semaglutide with other oral agents, in the PIONEER 2 open-label trial, oral semaglutide (14 mg once daily) was evaluated against the sodium-glucose co-transporter 2 inhibitor (SGLT2i) empagliflozin (25 mg once daily) for 52 weeks in 822 patients with T2D uncontrolled on metformin with a mean HbA1c level of 8.1%

not medical advice

Knowing that 2.4 mg corresponds to 48 units empowers individuals to accurately administer their medication, maximizing its effectiveness while minimizing risks

Yang JY, Wang T, Pate V, Buse JB, Sturmer T

What should be considered when combining keto and GLP-1 medications